Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

VALN - Valneva SE Latest News | Finranks

Home

VALN

(VALN)

NMS – Real Time Price. Currency in USD

6.17

-0.15 (-2.37%)

At close: Mar 27, 2026, 4:00 PM EDT

6.60

+0.43 (6.97%)

After-hours: Mar 27, 2026, 7:52 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Videos

No Data

There is no data to display

Press releases

Valneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DC

Valneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DC

Lyon (France), March 26, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its participation in the upcoming 26th World Vaccine Congress, which will take place from March 31 to April 2, 2026 at the Walter E. convention center in Washington, D.C.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN

NEW YORK, March 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE – VALN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE – VALN

NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE (“Valneva” or the “Company”) (NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial

NEW YORK & LYON, France--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced topline results from the Phase 3 VALOR “Vaccine Against Lyme for Outdoor Recreationists” clinical trial (NCT05477524) of its investigational 6-valent OspA-based Lyme disease vaccine candidate PF-07307405 (LB6V, formerly known as VLA15) demonstrating: In the pre-specified analyses: Efficacy of 73.2% from 28 days post-dose 4 (season 2) in reducing the rate of confir.